GB0821994D0 - In viva imaging method - Google Patents

In viva imaging method

Info

Publication number
GB0821994D0
GB0821994D0 GBGB0821994.1A GB0821994A GB0821994D0 GB 0821994 D0 GB0821994 D0 GB 0821994D0 GB 0821994 A GB0821994 A GB 0821994A GB 0821994 D0 GB0821994 D0 GB 0821994D0
Authority
GB
United Kingdom
Prior art keywords
imaging method
viva imaging
viva
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0821994.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Priority to GBGB0821994.1A priority Critical patent/GB0821994D0/en
Publication of GB0821994D0 publication Critical patent/GB0821994D0/en
Priority to EP09768015A priority patent/EP2389200A2/en
Priority to US13/132,109 priority patent/US20110236307A1/en
Priority to PCT/EP2009/066120 priority patent/WO2010063701A2/en
Priority to CN2009801562662A priority patent/CN102300589A/zh
Priority to JP2011538991A priority patent/JP2012510499A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0821994.1A 2008-12-02 2008-12-02 In viva imaging method Ceased GB0821994D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0821994.1A GB0821994D0 (en) 2008-12-02 2008-12-02 In viva imaging method
EP09768015A EP2389200A2 (en) 2008-12-02 2009-12-01 In vivo imaging method for parkinson's disease
US13/132,109 US20110236307A1 (en) 2008-12-02 2009-12-01 In vivo imaging method
PCT/EP2009/066120 WO2010063701A2 (en) 2008-12-02 2009-12-01 In vivo imaging method
CN2009801562662A CN102300589A (zh) 2008-12-02 2009-12-01 用于帕金森氏病症的体内成像方法
JP2011538991A JP2012510499A (ja) 2008-12-02 2009-12-01 生体内イメージング法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0821994.1A GB0821994D0 (en) 2008-12-02 2008-12-02 In viva imaging method

Publications (1)

Publication Number Publication Date
GB0821994D0 true GB0821994D0 (en) 2009-01-07

Family

ID=40262535

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0821994.1A Ceased GB0821994D0 (en) 2008-12-02 2008-12-02 In viva imaging method

Country Status (6)

Country Link
US (1) US20110236307A1 (cg-RX-API-DMAC7.html)
EP (1) EP2389200A2 (cg-RX-API-DMAC7.html)
JP (1) JP2012510499A (cg-RX-API-DMAC7.html)
CN (1) CN102300589A (cg-RX-API-DMAC7.html)
GB (1) GB0821994D0 (cg-RX-API-DMAC7.html)
WO (1) WO2010063701A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101297815B1 (ko) * 2010-11-18 2013-09-03 충남대학교산학협력단 폴리감마글루탐산과 광학영상다이의 복합체를 함유하는 센티넬 림프노드 감지용 광학영상 프로브
CA2945938C (en) 2014-06-25 2023-04-18 Nucana Biomed Limited Gemcitabine prodrugs
AU2017231781C1 (en) 2016-03-11 2021-12-16 Ac Immune Sa Bicyclic compounds for diagnosis and therapy
CN120987917A (zh) 2016-12-29 2025-11-21 箕星药业香港有限公司 金属酶抑制剂化合物
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
KR20240038149A (ko) 2017-04-26 2024-03-22 바실리어 파마슈티카 인터내셔널 리미티드 푸라자노벤즈이미다졸 및 이의 결정 형태의 제조 공정
US11844846B2 (en) 2018-05-16 2023-12-19 Emory University Styrylbenzothiazole derivatives and uses in imaging methods
CA3102038A1 (en) 2018-06-08 2019-12-12 Ac Immune Sa Novel compounds for diagnosis
US20200085979A1 (en) 2018-09-11 2020-03-19 Stanley Satz Precision medicine theranostics and diagnostics a combination thereof
CA3126224A1 (en) 2019-01-08 2020-07-16 Phasebio Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR20230008183A (ko) 2020-05-07 2023-01-13 에이씨 이뮨 에스에이 진단을 위한 신규한 화합물
AU2022385416A1 (en) 2021-11-10 2024-05-02 Ac Immune Sa 4h-imidazo[1,5-b]pyrazole derivatives for diagnosis
CN118510781A (zh) 2021-11-10 2024-08-16 Ac免疫有限公司 二氢吡咯并[3,4c]-吡唑衍生物及其在诊断中的用途
EP4430044A1 (en) 2021-11-10 2024-09-18 AC Immune SA Dihydropyrrolo[3,4-c]pyrazole derivatives and their use in diagnosis
WO2024126840A1 (en) 2022-12-16 2024-06-20 Ac Immune Sa Novel compounds for diagnosis
CN120344535A (zh) 2022-12-16 2025-07-18 Ac免疫有限公司 用于诊断的新化合物
WO2025037013A1 (en) 2023-08-16 2025-02-20 Ac Immune Sa Diagnostic compounds that bind to alpha-synuclein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6379650B1 (en) * 2001-03-19 2002-04-30 Wesley Scott Ashton Technetium 99m-N2S2-congo red complexes utilizing diamide dithiolate ligand systems for radioimaging
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US8329142B2 (en) * 2003-05-29 2012-12-11 Pettegrew Jay W Compounds, compositions and methods for medical imaging of Parkinson's disease
WO2007011834A2 (en) * 2005-07-15 2007-01-25 The Regents Of The University Of California Compounds and method for the diagnosis and treatment of amyloid associated diseases
JP2009519239A (ja) * 2005-12-01 2009-05-14 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾチアゾール化合物
US20080118938A1 (en) * 2006-09-06 2008-05-22 Lisbell Estrada Methods and Compositions for the Detection of Protein Folding Disorders
BRPI0719763A2 (pt) * 2006-10-02 2014-01-28 Ac Immune Sa Anticorpo, molécula de ácido nucleico, vetor de expressão, célula, composição, mistura, uso de um anticorpo quimérico ou um fragmento do mesmo ou um anticorpo humanizado ou um fragmento do mesmo e/ou uma parte funcional e/ou uma composição farmacêutica ou uma mistura, métodos para a preparação de uma composição farmacêutica ou de uma mistura, para prevenir, tratar ou aliviar os efeitos de uma doença, de diagnóstico de uma doença ou condição associada com amilóide em um paciente e de determinação do grau da carga de placa amiloidogênica em um tecido e/ou fluidos corporais, kits de teste para a detecção e diagnóstico de doenças e condições associadas com amilóide, região variável de cadeia leve, região variável de cadeia pesada, linhagem de célula, gene de anticorpo, e, métodos para desagregar fibras de beta-amilóide pré formadas, para prevenir a degradação de neurônio induzida por abeta, para diagnosticar uma predisposição a uma doença ou condição associada com amilóide em um paciente, para monitorar doença residual mínima em um paciente, para prognosticar a responsividade de um paciente que é tratado com um anticorpo ou uma composição de vacina, para reduzir a carga de placa no cérebro de um animal, para reduzir a quantidade de placas no cérebro de um animal, para diminuir a quantidade total de abeta solúvel no cérebro de um animal e para reter ou aumentar a capacidade de memória cognitiva em um mamífero.
EP2171478A4 (en) * 2007-03-30 2013-01-30 Univ California IN VIVO IMAGING METHOD FOR SULPHOTRANSFERASES

Also Published As

Publication number Publication date
US20110236307A1 (en) 2011-09-29
WO2010063701A2 (en) 2010-06-10
JP2012510499A (ja) 2012-05-10
CN102300589A (zh) 2011-12-28
EP2389200A2 (en) 2011-11-30
WO2010063701A3 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
GB0821994D0 (en) In viva imaging method
GB0820927D0 (en) Method
AP2015008431A0 (en) Improvements in feedwells
GB0818093D0 (en) Method
GB0803107D0 (en) Method
GB0822836D0 (en) Method
GB0810418D0 (en) Method
GB0804981D0 (en) Method
GB0813599D0 (en) Method
GB0807409D0 (en) Method
GB0815428D0 (en) Method
GB0804690D0 (en) Method
GB0807410D0 (en) Method
GB0906449D0 (en) Improvements in imaging
GB0809404D0 (en) Method
ZA201101329B (en) Recarburisation method
GB0818738D0 (en) Imaging neuroflammation
ZA201008728B (en) Method
GB0818151D0 (en) Imaging techniques
GB0813494D0 (en) Method
GB0805862D0 (en) Method
GB0922037D0 (en) Method
GB0812102D0 (en) Method
GB0806186D0 (en) Method
GB0811166D0 (en) Method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)